Seeking Alpha

Acorda Therapeutics (ACOR +1.9%) hits new 52-week highs after it reported better-than-expected...

Acorda Therapeutics (ACOR +1.9%) hits new 52-week highs after it reported better-than-expected results for Q4. Revenue for the quarter came in at $81.5 million, beating the $78.90 million consensus. Additonally, the company says it plans to submit an NDA to the FDA for a diazepam nasal spray in 2013.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector